Patrick Henrick

589 total citations
12 papers, 166 citations indexed

About

Patrick Henrick is a scholar working on Hematology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Patrick Henrick has authored 12 papers receiving a total of 166 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 6 papers in Pathology and Forensic Medicine and 4 papers in Molecular Biology. Recurrent topics in Patrick Henrick's work include Lymphoma Diagnosis and Treatment (5 papers), Acute Myeloid Leukemia Research (4 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Patrick Henrick is often cited by papers focused on Lymphoma Diagnosis and Treatment (5 papers), Acute Myeloid Leukemia Research (4 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Patrick Henrick collaborates with scholars based in United States, Sweden and Australia. Patrick Henrick's co-authors include Paul G. Richardson, Stacey Chuma, Irene M. Ghobrial, Jacob P. Laubach, Robert Redd, Pamela S. Becker, Raymond P. Perez, Kalvis Hornburg, Kenneth C. Anderson and Peter Sabbatini and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Patrick Henrick

11 papers receiving 166 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Patrick Henrick United States 7 83 76 73 56 40 12 166
Ndegwa Njuguna United States 5 47 0.6× 87 1.1× 40 0.5× 53 0.9× 91 2.3× 8 184
Alexandra Savell United States 7 98 1.2× 78 1.0× 73 1.0× 72 1.3× 143 3.6× 15 240
Julia Gutjahr Austria 6 92 1.1× 47 0.6× 31 0.4× 95 1.7× 49 1.2× 8 174
Stefanie Kreutmair Germany 9 49 0.6× 88 1.2× 53 0.7× 40 0.7× 17 0.4× 21 173
Jared Henderson United States 5 55 0.7× 38 0.5× 20 0.3× 48 0.9× 45 1.1× 14 131
Madelon M.E. de Jong Netherlands 6 86 1.0× 105 1.4× 131 1.8× 96 1.7× 29 0.7× 14 235
Tobias Roider Germany 8 62 0.7× 67 0.9× 18 0.2× 79 1.4× 41 1.0× 19 175
Sven Turkalj United Kingdom 5 31 0.4× 47 0.6× 34 0.5× 39 0.7× 40 1.0× 9 114
Katherine E. Pendleton United States 5 102 1.2× 97 1.3× 99 1.4× 92 1.6× 23 0.6× 11 219
Giorgia Chiodin United Kingdom 7 36 0.4× 74 1.0× 51 0.7× 67 1.2× 156 3.9× 14 203

Countries citing papers authored by Patrick Henrick

Since Specialization
Citations

This map shows the geographic impact of Patrick Henrick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Henrick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Henrick more than expected).

Fields of papers citing papers by Patrick Henrick

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Henrick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Henrick. The network helps show where Patrick Henrick may publish in the future.

Co-authorship network of co-authors of Patrick Henrick

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Henrick. A scholar is included among the top collaborators of Patrick Henrick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Henrick. Patrick Henrick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
2.
Lue, Jennifer Kimberly, Don A. Stevens, Emmeline Ayers, et al.. (2023). PHASE 1 TRIAL OF KT‐413, A DEGRADER OF IRAK4 AND IMID SUBSTRATES, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN’S LYMPHOMAS. Hematological Oncology. 41(S2). 808–809.
3.
Stevens, Don A., Reginald B. Ewesuedo, Alice McDonald, et al.. (2022). Phase 1 study of KT-413, a targeted protein degrader, in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma.. Journal of Clinical Oncology. 40(16_suppl). TPS3170–TPS3170. 9 indexed citations
4.
Lue, Jennifer Kimberly, Don A. Stevens, Michael E. Williams, et al.. (2022). Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. Blood. 140(Supplement 1). 12143–12144. 7 indexed citations
5.
Ghobrial, Irene M., Chia‐Jen Liu, Robert Redd, et al.. (2019). A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. Clinical Cancer Research. 26(2). 344–353. 79 indexed citations
6.
Cortes, Jörge E., Eunice S. Wang, Justin M. Watts, et al.. (2019). Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine. Blood. 134(Supplement_1). 674–674. 16 indexed citations
7.
8.
9.
Laubach, Jacob P., Ajay K. Nooka, Craig E. Cole, et al.. (2017). An open-label, single arm, phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma.. Journal of Clinical Oncology. 35(15_suppl). 8002–8002. 13 indexed citations
10.
11.
Ghobrial, Irene M., Robert Redd, Philippe Armand, et al.. (2015). Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. Leukemia. 29(12). 2338–2346. 26 indexed citations
12.
Ghobrial, Irene M., Jacob P. Laubach, Kenneth H. Shain, et al.. (2014). Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma. Blood. 124(21). 5777–5777. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ndegwa Njuguna Breakdown of academic impact, for papers by Alexandra Savell Breakdown of academic impact, for papers by Julia Gutjahr Breakdown of academic impact, for papers by Stefanie Kreutmair Breakdown of academic impact, for papers by Jared Henderson Breakdown of academic impact, for papers by Madelon M.E. de Jong Breakdown of academic impact, for papers by Tobias Roider Breakdown of academic impact, for papers by Sven Turkalj Breakdown of academic impact, for papers by Katherine E. Pendleton Breakdown of academic impact, for papers by Giorgia Chiodin
Rankless by CCL
2026